MacroGenics (MGNX) Stock Rating Upgraded by ValuEngine
ValuEngine upgraded shares of MacroGenics (NASDAQ:MGNX) from a sell rating to a hold rating in a research report released on Thursday morning.
Several other research firms have also weighed in on MGNX. BidaskClub raised MacroGenics from a strong sell rating to a sell rating in a research report on Thursday, January 25th. Cowen reissued a buy rating on shares of MacroGenics in a research report on Wednesday, January 24th. Zacks Investment Research lowered MacroGenics from a hold rating to a sell rating in a research report on Friday, February 23rd. SunTrust Banks reissued a buy rating and issued a $31.00 price objective on shares of MacroGenics in a research report on Tuesday, January 23rd. Finally, BTIG Research reissued a buy rating and issued a $28.00 price objective on shares of MacroGenics in a research report on Tuesday, January 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $28.13.
MacroGenics (NASDAQ:MGNX) traded up $1.91 during mid-day trading on Thursday, hitting $28.94. The stock had a trading volume of 549,193 shares, compared to its average volume of 263,957. MacroGenics has a 1 year low of $14.36 and a 1 year high of $29.35. The company has a market cap of $1,070.00, a price-to-earnings ratio of -46.68 and a beta of 2.52.
Several institutional investors and hedge funds have recently modified their holdings of MGNX. Parametric Portfolio Associates LLC acquired a new stake in shares of MacroGenics in the 2nd quarter valued at about $203,000. Teacher Retirement System of Texas acquired a new stake in shares of MacroGenics in the 4th quarter valued at about $225,000. MetLife Investment Advisors LLC acquired a new stake in shares of MacroGenics in the 4th quarter valued at about $281,000. Private Capital Advisors Inc. acquired a new stake in shares of MacroGenics in the 4th quarter valued at about $332,000. Finally, Virtus Fund Advisers LLC acquired a new stake in shares of MacroGenics in the 4th quarter valued at about $343,000. Institutional investors own 85.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: “MacroGenics (MGNX) Stock Rating Upgraded by ValuEngine” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2018/03/04/macrogenics-mgnx-stock-rating-upgraded-by-valuengine.html.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.